Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 10/20 | 0.33 |
| ▸ | HTR1A | P08908 | 9/20 | 0.33 |
| ▸ | HTR2A | P28223 | 9/20 | 0.33 |
| ▸ | CCKAR | P32238 | 1/20 | 0.31 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1050913 | 0.81 | GSK3B (0.41) | GSK3BKDM4EMEN1MAPTKMT2A | |
| SCHEMBL2267176 | 0.75 | PIM1 (0.41) | GSK3BGSK3A | |
| SCHEMBL2544260 | 0.73 | PTPN1 (0.53) | GSK3BKDM4EALDH1A1MAPTKDM4C | |
| SCHEMBL27664385 | 0.73 | GSK3B (0.50) | GSK3BKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL121405 | 0.73 | GSK3B (0.50) | GSK3BKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL5153625 | 0.73 | ADRA2A (0.56) | ADRA2AADRA2BGSK3BGSK3ADRD2 | |
| SCHEMBL11120799 | 0.72 | GSK3B (0.48) | GSK3BKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL12078412 | 0.71 | CES1 (0.42) | GSK3B | |
| SCHEMBL8413957 | 0.71 | MEN1 (0.44) | GSK3BKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL27944869 | 0.71 | BACE1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294792-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-12-01 | — | — | US | disclosed |
| US-8058425-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-11-15 | — | — | US | disclosed |
| US-8022065-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110207721-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-08-25 | — | — | US | disclosed |
| US-20090105229-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-04-23 | — | — | US | disclosed |
| US-7491716-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | PNP, ADK, NME2 | ADRA2A 3273/4885ADRA2B 2483/4885GSK3B 386/4885 |
| US-20110294792-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | ADRA2A 3273/4885ADRA2B 2483/4885GSK3B 386/4885 |
| US-20110207721-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | ADRA2A 3273/4885ADRA2B 2483/4885GSK3B 386/4885 |
| US-20090105229-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | ADRA2A 3273/4885ADRA2B 2483/4885GSK3B 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.